Other currently ongoing clinical trials include NCT03417544 (atezolizumab, pertuzumab, TZ, HER2+ MBC), NCT03125928 (atezolizumab, paclitaxel, TZ, pertuzumab, HER2+ MBC), NCT03595592, (TZ, pertuzumab, carboplatin, paclitaxel, atezolizumab, HER2+, locally advanced BC), and NCT03199885 (paclitaxel, TZ, pertuzumab, atezolizumab, for HER2+ MBC). This evidence concerns the gene ERBB2 and breast cancer.